Cargando…
Sox2(+) cells in Sonic Hedgehog-subtype medulloblastoma resist p53-mediated cell-cycle arrest response and drive therapy-induced recurrence
BACKGROUND: High-intensity therapy effectively treats most TP53 wild-type (TP53-WT) Sonic Hedgehog-subgroup medulloblastomas (SHH-MBs), but often cause long-term deleterious neurotoxicities in children. Recent clinical trials investigating reduction/de-escalation of therapy for TP53-WT SHH-MBs cause...
Autores principales: | Treisman, Daniel M, Li, Yinghua, Pierce, Brianna R, Li, Chaoyang, Chervenak, Andrew P, Tomasek, Gerald J, Lozano, Guillermina, Zheng, Xiaoyan, Kool, Marcel, Zhu, Yuan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6860004/ https://www.ncbi.nlm.nih.gov/pubmed/31763624 http://dx.doi.org/10.1093/noajnl/vdz027 |
Ejemplares similares
-
Clinical and molecular analysis of smoothened inhibitors in Sonic Hedgehog medulloblastoma
por: Pereira, Victor, et al.
Publicado: (2021) -
HDL nanoparticles targeting sonic hedgehog subtype medulloblastoma
por: Bell, Jonathan B., et al.
Publicado: (2018) -
Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma
por: Brun, Sonja N., et al.
Publicado: (2014) -
MBCL-21. GERMLINE ELONGATOR MUTATIONS IN SONIC HEDGEHOG MEDULLOBLASTOMA
por: Robinson, Giles W, et al.
Publicado: (2020) -
Genetic drivers of metastatic dissemination in sonic hedgehog medulloblastoma
por: Jenkins, Noah C, et al.
Publicado: (2014)